(Reuters) -Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage study, but that was less than previous trial results for Novo ...

There were a few different things that were the seeds planted that then grew into Only Philanthropy. I had been doing fundraisers on Cameo that I'd been donating to different organizations, and it was ...

People who are in need of weight loss medications but do not have insurance coverage will soon have a new way to access one of the popular medications, Zepbound. Eli Lilly, the maker of Zepbound, ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage study that sets the stage for a new entrant to the obesity market next year.

Aug 26 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of body weight in a late-stage trial, after ...

Higher 36 mg dose of orforglipron leads to 12.4% weight loss vs 0.9% for placebo Dropout rate due to side effects was about 10% for high-dose patients Lilly plans to file for approval of once-daily ...